RB 201 - Rarefied Biosciences
Alternative Names: RB201Latest Information Update: 27 Mar 2026
At a glance
- Originator Rarefied Biosciences
- Class Immunotherapies
- Mechanism of Action MALT1 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
Most Recent Events
- 27 Mar 2026 Phase-I clinical trials in Autoimmune disorders in USA (PO) (Rarefied Biosciences website, April 2026)